BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9111301)

  • 1. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
    Friedlos F; Denny WA; Palmer BD; Springer CJ
    J Med Chem; 1997 Apr; 40(8):1270-5. PubMed ID: 9111301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
    Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
    J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase.
    Friedlos F; Court S; Ford M; Denny WA; Springer C
    Gene Ther; 1998 Jan; 5(1):105-12. PubMed ID: 9536271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
    Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
    J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
    J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
    Johansson E; Parkinson GN; Denny WA; Neidle S
    J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
    Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
    J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase.
    Atwell GJ; Boyd M; Palmer BD; Anderson RF; Pullen SM; Wilson WR; Denny WA
    Anticancer Drug Des; 1996 Oct; 11(7):553-67. PubMed ID: 8921936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.
    Hay MP; Wilson WR; Denny WA
    Bioorg Med Chem; 2005 Jun; 13(12):4043-55. PubMed ID: 15911317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
    Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
    J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
    Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
    Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
    J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
    Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
    Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.
    Anlezark GM; Melton RG; Sherwood RF; Wilson WR; Denny WA; Palmer BD; Knox RJ; Friedlos F; Williams A
    Biochem Pharmacol; 1995 Aug; 50(5):609-18. PubMed ID: 7669063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
    Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
    Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapy.
    Asche C; Dumy P; Carrez D; Croisy A; Demeunynck M
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1990-4. PubMed ID: 16442795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
    Bailey SM; Knox RJ; Hobbs SM; Jenkins TC; Mauger AB; Melton RG; Burke PJ; Connors TA; Hart IR
    Gene Ther; 1996 Dec; 3(12):1143-50. PubMed ID: 8986441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
    Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
    J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.